Videssa® Breast: Cancer Blood Test

Designed specifically for the early detection of breast cancer in women with abnormal imaging findings

mammogram-screening-patient-doctor-analysis-1128870494(1)

A simple blood test to detect breast cancer with high accuracy in women with abnormal imaging findings

A protein-based blood test combining Serum protein biomarkers (SPBs) with Tumor Associated Autoantibodies (TAAbs).

Previously CLIA certified

Launch as an LDT in USA

Latest Clinical Data

Todos Medical has collected over 1,000 clinical samples in several clinical trials for breast and other cancers conducted at the Wolfson Medical Center (Holon, Israel), Rabin Medical Center (Petach Tikva, Israel), Ichilov Medicalcenter (Tel Aviv, Israel) and in the Ukraine.

The latest clinical trial for Todos Medical’s breast cancer test included 59 patients and achieved 93% sensitivity and 87% specificity, as compared to routine mammography screening.

59 patients

 underwent treatment

93%

sensitivity

87%

specificity

Todos Breast Screens (TM-B1, TM-B2)

Our breast cancer blood test targets a large population of women who need to be checked regularly for breast cancer, whether that is because they are in a high-risk group or in an age group that should be routinely screened. It is recommended that all women over 40 undergo breast screening. The recommended testing protocols using mammography and ultrasound have limitations and discomfort.

Our proprietary TM-B1 cancer test will support current cancer diagnostic protocols at their weak points (like dense breast tissue in young women) and provide a simple and low-cost solution for early detection.

Our proprietary TM-B2 cancer screen will allow health care providers to distinguish between benign and malignant breast tumors.

30 million

women undergo mammography annually in the United States

15.5 million

women undergoing mammography
have dense breasts
 

32 states

have passed legislation that patients be informed of their breast density

The TBIA Platform

Platform for screening of all cancers, starting with Breast Screens (TM-B1, TM-B2) and Colon Screen (TM-C1)

The Total Biochemical Infrared Analysis (TBIA) platform is a proprietary process for screening of solid tumors using peripheral blood spectroscopy analysis.

sign-up-image

Stay informed of our latest breakthroughs.